Medical non-thermal plasma (NTP) treatments for various types of cancers have been reported. Cells with tumorigenic potential (cancer-initiating cells; CICs) are few in number in many types of tumors. CICs efficiently eliminate anti-cancer chemicals and exhibit high-level aldehyde dehydrogenase (ALDH) activity. We previously examined the effects of direct irradiation via NTP on cancer cells; even though we targeted CICs expressing high levels of ALDH, such treatment affected both non-CICs and CICs. Recent studies have shown that plasma-activated medium (PAM) (culture medium irradiated by NTP) selectively induces apoptotic death of cancer but not normal cells. Therefore, we explored the anti-cancer effects of PAM on CICs among endometrioid carcinoma and gastric cancer cells. PAM reduced the viability of cells expressing both low and high levels of ALDH. Combined PAM/cisplatin appeared to kill cancer cells more efficiently than did PAM or cisplatin alone. In a mouse tumor xenograft model, PAM exerted an anti-cancer effect on CICs. Thus, our results suggest that PAM effectively kills both non-CICs and CICs, as does NTP. Therefore, PAM may be a useful new anticancer therapy, targeting various cancer cells including CICs.
Plasma medicine is a new academic field combining plasma physics, life sciences, and clinical medicine. Plasma is the fourth physical state of matter, consisting of gas, electrons, ions, radicals, and ultraviolet light. Plasma is a hot ionized gas; some earlier medical applications of plasma exploited its thermal effects specifically. Heat and high temperatures have long been medically used to remove tissue and to sterilize and cauterize. 1, 2 However, non-thermal plasma (NTP), also known as cold atmospheric plasma or lowtemperature plasma, which is < 40°C at the time of application, has been developed within the past 25 years. 3 Recent studies have used such plasma, derived from an NTP source, to aid wound-healing, blood coagulation without cauterization, and cancer therapy. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Cells with tumorigenic potential, termed cancer-initiating cells (CICs), are few in number in many tumors such as leukemia 14 and breast, 15, 16 brain, 17 prostate, 18 and colon cancers. 19, 20 CICs are believed to trigger cancer recurrence and metastasis. They efficiently transport anti-cancer drugs to the external medium and are resistant to radiotherapy. CICs express high levels of cell membrane-associated ATPbinding cassette transporters, which play important roles in the efflux of anti-cancer drugs. 21, 22 A high level of aldehyde dehydrogenase (ALDH) activity is recognized as a CIC marker in many tumors. 16, [23] [24] [25] [26] ALDH oxidizes retinol to retinoic acid during the early stages of stem cell differentiation, and hematopoietic and neural stem cells exhibit high ALDH activity levels, 27 as do the CICs of human acute myeloid leukemia, plasma cell myeloma, glioma, and lung cancers. 16, 25, 26 Patients with uterine endometrioid carcinoma associated with high proportions of cells expressing elevated levels of ALDH were found to have poor prognoses. 24 We previously showed that direct NTP treatment affected both the non-CICs and CICs of human, uterine, endometrioid carcinoma cells and poorly differentiated, human gastric carcinoma cells; we used ALDH as a marker of CICs. 28, 29 Recently, the effects of plasma-activated medium (PAM) on various types of cancers have been evaluated. 7, 9, [30] [31] [32] PAM, which is produced by NTP treatment of culture medium, selectively induced apoptotic death of glioblastoma cells but not normal astrocyte cells. 7 However, the effect of PAM on CICs remains unknown. Therefore, we investigated the anti-cancer effect of PAM on CICs. Additionally, we examined the effects of PAM combined with an anti-cancer agent in a mouse tumor xenograft model.
MATERIALS AND METHODS

Cell lines
Human endometrial carcinoma HEC-1 cells were obtained from the Health Science Research Resource Bank of Osaka, Japan. The poorly differentiated human gastric cancer GCIY cell line was a kind gift from Dr. Hayao Nakanishi (Aichi Cancer Center, Japan). 33 Both cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Wako, Osaka, Japan) supplemented with 10% (v/ v) fetal bovine serum (Biosera, Kansas, MO, USA).
The source of NTP and PAM
The NTP source at Nagoya University was connected to a 60 Hz AC high-voltage power source (10 kV 0-p ) via an argon gas flow (flow rate: 2 standard L/min). The plasma plume extended approximately 6 mm above the exit in the absence of a target; the slit-width of the exit was 20 mm. . A schematic of the experimental procedure is shown in Figure 1 . DMEM (8 mL in a 60 mm dish; cat. no. 5796; Sigma, St. Louis, MO, USA) was typically positioned 3 mm below the plasma source and irradiated downstream of the plasma plume of the NTP device for 300 s. As in our previous report, the hydrogen peroxide (H 2 O 2 ) concentration of PAM was 227 mM.
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Cell viability assay Cells (1 Â 10 4 ) treated with PAM were plated in 100 mL medium in 96-well plates. On the following day, cell viability was assessed using the Premix WST-1 Cell Proliferative Assay System (Takara Bio Inc., Kyoto, Japan) according to the manufacturer's instructions. The absorbance at 450 nm of PAM-treated cells was subtracted from the background absorbance (600 nm). The values were expressed relative to those of cells not treated with PAM, and the results are presented as viability indices.
Intracellular reactive oxygen species (ROS) assay
Cells were incubated with 10 mM 5-/6-chloromethyl-2 0 ,7 0 -dichlorodihydrofluorescein diacetate, acetyl ester (CM-H 2 DCFDA; Invitrogen, Carlsbad, CA, USA) at 37°C for 20 minutes. Dead cells were stained with propidium iodide (PI). Cells producing high levels of ROS stained green, and dead cells stained red. Staining was observed under a fluorescence microscope (BZ-8000, KEYENCE, Osaka, Japan).
Immunocytochemical detection of cleaved caspase-3
Cleaved caspase-3, an apoptotic marker, was detected immunocytochemically using an anti-cleaved caspase-3 antibody (Cell Signaling Technology Inc., Beverly, MA, USA). Untreated cells and cells treated with PAM for 300 minutes were cytospun onto poly-L-lysine-coated glass slides at 1,500 rpm for 3 minutes, fixed in 10% (v/v) formalin for 5 minutes, and treated with 0.25% (v/v) Triton X-100 solution for 5 minutes. After incubation in peroxidase-blocking solution (DAKO A/S, Glostrup, Denmark) for 5 minutes, cells were incubated with the anti-cleaved caspase-3 antibody (1:300 dilution), and binding was evaluated using the ChemMate EnVision kit (DAKO). Diaminobenzidine (DAKO) served as the chromogen. As the negative control, staining was performed in the absence of primary antibody.
ALDH activity measurement and isolation of cells expressing low and high levels of ALDH
To detect and isolate ALDH-high cells, we used the Aldefluor kit (Stem Cell Technologies, Vancouver, BC, Canada) according to the manufacturer's instructions and the methods of previous reports. 28, 29 Briefly, cells were suspended in Aldefluor assay buffer containing an ALDH substrate and BODIPY-aminoacetaldehyde. The latter reagent is taken up by living cells and converted by intracellular ALDH to BODIPY-aminoacetate, which exhibits bright fluorescence; such cells were detected using the FACS Canto II or FACS Aria II flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). As a negative control, cells were stained under identical conditions in the presence of the specific ALDH inhibitor diethylaminobenzaldehyde (Stem Cell Technologies). Data were analyzed with the aid of Cell Quest software (BD Biosciences). Cells exhibiting faint and bright fluorescence were defined as ALDH-low and ALDHhigh cells, respectively. To explore the effects of PAM on ALDH activity, 3 Â 10 5 cells treated with PAM or untreated were plated in 3 mL medium in six-well plates and, on the next day, were subjected to the Aldefluor assay.
Effects of the anti-cancer drug cisplatin with or without PAM
Cisplatin (Sigma-Aldrich, St. Louis, MO, USA) is commonly used to treat various types of cancer. We examined the effects of cisplatin on non-sorted cells treated with PAM or untreated. Cells (1 Â 10 4 ) were seeded into 96-well cell culture plates with 100 mL DMEM/10% [v/v] FBS/well and PAM or DMEM containing various concentrations of cisplatin (0, 1, 100, or 300 mM). On the following day, cell viability was assessed using the Premix WST-1 Cell Proliferative Assay System. Additionally, we compared the effects of cisplatin with versus without PAM on sorted ALDH-high and ALDH-low cells.
Xenograft transplantation prior to PAM treatment in mice
For in vivo studies, 5-7-week-old female non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice were purchased from Charles River Laboratories (Yokohama, Japan) and housed under specific-pathogenfree conditions. Before xenotransplantation, the mice were heavily anesthetized with a combination of medetomidine hydrochloride 0.3 mg/kg (Nippon Zenyaku Kogyo, Fukushima, Japan), midazolam 4 mg/kg (Astellas Pharma, Tokyo, Japan), and butorphanol tartrate 5 mg/kg (Meiji Seika Pharma, Tokyo, Japan). For xenotransplantation, each mouse was injected with 1.5 Â 10 5 cells. Sorted ALDHhigh tumor cells were suspended in 0.2 mL Matrigel (BD Biosciences) and injected into the abdominal cavity. PAM or control DMEM (1 mL) was injected into the abdominal cavity on days 0, 1, 2, 6, 7, and 8 after tumor cell injection. The intraperitoneal tumor size was estimated by abdominal palpation of cancer cell-injected and noninjected mice. Tumor volume was calculated as (width) 2 Â (length)/2 (Meyer-Siegler et al. 34 ). All animal experiments followed the guidelines of the Osaka University Animal Center and were approved by the relevant institutional review board (the Committee for Animal Experiments; approval no. 25-089-004).
STATISTICAL ANALYSIS
Statistical analysis was performed using the Student's ttest. All values are presented as means AE standard error of at least three experiments. A P value < 0.05 was considered to reflect statistical significance.
RESULTS
Effects of PAM on cancer cells
We examined the effects of PAM on HEC-1 and GCIY cells. PAM significantly reduced the cell viability of both cell types compared with untreated cells (Fig. 2a) . PAM reduced the viability indices of HEC-1 and GCIY cells to approximately 40% and 25%, respectively.
ROS production after PAM treatment of cancer cells and immunocytochemical detection of cleaved caspase-3
Plasma irradiation induces production of ROS such as H 2 O 2 . To investigate intracellular ROS in cancer cells after PAM treatment, cells were incubated with CM-H 2 DCFDA and observed under a fluorescence microscope. The number of cells expressing high levels of ROS gradually increased, commencing 30 minutes after PAM treatment, and almost all cells were stained with PI by 300 minutes (Fig. 2b) . The proportion of cleaved caspase-3-positive cells was higher among PAM-treated than untreated cells (Fig.  2c) .
Effects of PAM combined with an anti-cancer drug
To compare the effect of PAM with that of an anti-cancer drug, PAM was combined with the antineoplastic alkylating agent cisplatin. Treatment with PAM alone (undiluted and twofold and fourfold diluted) reduced the viability indices of HEC-1 cells to 0.22, 0.75, and 0.98; treatment with cisplatin alone at 1, 100, and 300 mM reduced the indices to 0.97, 0.79, and 0.58, respectively. Undiluted PAM combined with 1, 100, and 300 mM cisplatin reduced the indices to 0.16, 0.10, and 0.08, respectively (Fig. 3a) . The indices decreased to 0.83, 0.51, and 0.20 when twofold-diluted PAM was combined with 1, 100, and 300 mM cisplatin and to 1.03, 0.88, and 0.54 when fourfold-diluted PAM was combined with 1, 100, and 300 mM cisplatin, respectively. Similarly, PAM alone (undiluted and twofold and fourfold diluted) reduced the viability indices of GCIY cells to 0.42, 0.96, and 1.10, and treatment with 1, 100, and 300 mM cisplatin alone reduced the indices to 0.92, 0.75, and 0.80, respectively. Combined PAM/cisplatin treatment reduced the indices to 0.67, 0.21, and 0.12 when undiluted PAM was combined with 1, 100, and 300 mM cisplatin, respectively (Fig. 3b) . The indices decreased to 1.31, 0.32, and 0.20 when twofold-diluted PAM was combined with 1, 100, and 300 mM cisplatin and to 1.69, 0.59, and 0.35 when fourfold-diluted PAM was combined with 1, 100, and 300 mM cisplatin, respectively. 
Effect of PAM on ALDH activity
To explore the effect of PAM on ALDH activity (a CIC marker), the Aldefluor assay was used to evaluate HEC-1 and GCIY cells treated with PAM or untreated cells. PAM reduced the ALDH-high proportion from 10.7% to 1.4% in HEC-1 cells and from 5.6% to 0% in GCIY cells (Fig. 4) .
Effect of PAM with or without cisplatin on sorted ALDHlow and Àhigh cells
ALDH-low and Àhigh cells were sorted by flow cytometry and treated with PAM. In HEC1 cells, PAM reduced the viability index of sorted ALDH-low and Àhigh cells to 0.32 (Fig. 5a) ; similar results were seen when GCIY cells were evaluated (Fig. 5b) . In ALDH-low cells, treatment with 1, 100, and 300 mM cisplatin alone reduced the viability indices to 1.04, 0.89, and 0.85, respectively. Combined PAM/ cisplatin reduced the indices to 0.35, 0.20, and 0.18 when PAM was combined with 1, 100, and 300 mM cisplatin, respectively (Fig. 5a) . Treatment of ALDH-high cells with PAM alone reduced the HEC-1 viability index to 0.42, and treatment with cisplatin alone at 1, 100, and 300 mM reduced the indices to 1.43, 1.48, and 1.14, respectively. Treatment with PAM/cisplatin reduced the indices to 0.28, 0.24, and 0.25 at cisplatin concentrations of 1, 100, and 300 mM, respectively (Fig. 5a) . In ALDH-low GCIY cells, treatment with PAM alone reduced the viability index to 0.65, and treatment with 1, 100, and 300 mM cisplatin alone reduced the indices to 1.35, 1.15, and 0.53, respectively. PAM/cisplatin treatment reduced the indices to 0.23, 0.11, and 0.10 at cisplatin levels of 1, 100, and 300 mM, respectively (Fig. 5b) . In ALDH-high cells, treatment with PAM alone reduced the index to 0.48, and treatment with 1, 100, and 300 mM cisplatin alone reduced the indices to 3.07, 3.01, and 1.51, respectively. PAM/cisplatin treatment reduced the indices to 0.12, 0.04, and 0.10 at cisplatin levels of 1, 100, and 300 mM, respectively (Fig. 5b) . PAM thus reduced the viability indices of ALDH-high and Àlow cells to similar extents.
Effect of PAM on mouse tumor xenografts
To explore the effect of PAM in vivo, we evaluated mice bearing xenografts of a human endometrioid carcinoma. After ALDH-high tumor cells were injected into the abdominal cavities of NOD/SCID mice, PAM or control DMEM was injected. The tumor volume in DMEM-treated mice was larger than that in PAM-treated animals (Fig. 6a, b) .
DISCUSSION
NTP, a novel anti-cancer therapy, has recently been shown to improve outcomes in models of ovarian, brain, prostate, and colon cancers. [8] [9] [10] [11] [12] Similarly, PAM (culture medium subjected to NTP) selectively induced apoptosis of tumor but not normal cells. hours. Thus, both extrinsic and intrinsic ROS killed cancer cells. Recent studies have suggested that the anti-cancer effects of PAM feature several mechanisms, of which one is downregulation of survival and proliferation signaling pathways. PAM downregulated both the PI3K/AKT and the Ras/ MAPK signaling pathways, which induce cell growth and division and inhibit apoptosis, in glioblastoma cell lines. 31, 32 Also, PAM activated signaling pathways featuring death receptors such as the Fas ligand (FasL) receptor and tumor necrosis factor (TNF)-alpha receptor. Apoptotic signals are mediated by caspase cleavage cascades. When FasL and TNF-alpha bind to their receptors, caspase 8 is cleaved by the adaptor molecule Fas-associated death domain, activating downstream caspases to induce apoptosis. 31 We recently showed in a mouse model that the level of cleaved caspase-3, measured by immunohistochemistry, in endometrioid carcinoma cells increased after direct NTP irradiation. PAM may induce a similar apoptotic mechanism via the caspase pathway. Further studies are needed. When treating cancer, it is imperative to eliminate CICs associated with high risks of recurrence and metastasis; CICs transport anti-cancer drugs to the medium and are resistant to radiotherapy. 15, 16, 26, 35 A high level of ALDH expression abrogates the oxidative stress induced by ROS but also imparts resistance to anti-cancer agents such as oxazaphosphorine, taxane, and platinum drugs. 36 Here, we found that PAM reduced the proportion of ALDH-high cells, including that among CICs, and the viability indices of both ALDH-high and -low cells in endometrioid carcinoma cell and gastric cancer cell lines, as did direct NTP treatment. The components of PAM may directly inhibit ALDH, triggering cancer regression. However, further studies are required. Our results suggest that PAM affected both non-CICs and CICs in a similar manner to direct irradiation. Additionally, intra-abdominal PAM injection reduced proliferation of ALDH-high cells in mice bearing tumor xenografts. PAM affected CICs both in vitro and in vivo.
Our data show that PAM exhibited anti-cancer effects on CICs both in vitro and in vivo. In terms of cancer therapy, we recommend that PAM (with or without anti-cancer drugs) be tested in future studies. Although further studies on the mechanism involved are essential, PAM is a promising treatment option, contributing to a brighter therapeutic outlook.
